Abstract

Imatinib therapy for chronic myeloid leukemia: where do we go now?

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
EUTOS Score Is Not Predictive for Survival and Outcome in Patients (pts) with Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKIs) At MD Anderson Cancer Center (MDACC),
Aziz Nazha ... Hagop M Kantarjian
Blood | VOL. 118
Aziz Nazha, et. al.Aziz Nazha ... Hagop M Kantarjian
18 Nov 2011
Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP),
Maro Ohanian ... Jorge E Cortes
Blood | VOL. 118
Maro Ohanian, et. al.Maro Ohanian ... Jorge E Cortes
18 Nov 2011
What Does a Deep Molecular Response Signify?
Julieta Politi ... Neil P Shah
Journal of Clinical Oncology | VOL. 32
Julieta Politi, et. al.Julieta Politi ... Neil P Shah
02 Dec 2013
Clinical Significance of Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR) Achieved with Different Treatment Modalities Used As Frontline Therapy In Chronic Myeloid Leukemia (CML) Chronic Phase (CP)
Mona Lisa Alattar ... Jorge E Cortes
Blood | VOL. 118
Mona Lisa Alattar, et. al.Mona Lisa Alattar ... Jorge E Cortes
18 Nov 2011
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer.
Steven J Katz ... Allison W Kurian
Journal of Clinical Oncology | VOL. -
Steven J Katz, et. al.Steven J Katz ... Allison W Kurian
15 Jul 2024
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.
Yoon-Koo Kang ... Sung Hoon Noh
Journal of Clinical Oncology | VOL. -
Yoon-Koo Kang, et. al.Yoon-Koo Kang ... Sung Hoon Noh
12 Jul 2024
Individualized Local Recurrence Estimates for Ductal Carcinoma In Situ.
Laura E G Warren ... Jennifer R Bellon
Journal of Clinical Oncology | VOL. -
Laura E G Warren, et. al.Laura E G Warren ... Jennifer R Bellon
11 Jul 2024
Are Oral Selective Estrogen Receptor Degraders Beneficial for Patients With ESR1-Mutated Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer?
Aoba Okeya ... Chikako Shimizu
Journal of Clinical Oncology | VOL. -
Aoba Okeya, et. al.Aoba Okeya ... Chikako Shimizu
11 Jul 2024
View more papers